Competition & Peer Data API & CSV Delivery

Genocea Biosciences Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Genocea Biosciences Inc (GNCA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2022
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-68.38 %
Q1 2022
Net Margin
-5,917.78 %
Q1 2022

Key Findings: Genocea Biosciences Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 21M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-94.9% annualized vs trailing 12 months).
  • Peer revenue share: Genocea Biosciences Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

GNCA Sales vs. its Competitors, Q1 2022

Genocea Biosciences Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/GNCA/competitors
https://api.csimarket.com/api/v1/companies/GNCA/relationships
https://api.csimarket.com/api/v1/companies/GNCA/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs -68.4% for Genocea Biosciences Inc. Genocea Biosciences Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Genocea Biosciences Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Genocea Biosciences Inc No Yes Yes Yes
Similar Growth & Profitability (8) 12.50 % (1 of 8) 100.00 % (8 of 8) 100.00 % (8 of 8) 25.00 % (2 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q1 2022

100%market share
  • Genocea Biosciences Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Genocea Biosciences Inc and its 0 tracked competitors.

See Genocea Biosciences Inc's full market share breakdown »

GNCA Stock Performance relative to its Competitors

GNCA Competitors (weighted) Percent change over the selected range

GNCA Stock Performance relative to Similar Growth & Profitability Competitors

GNCA Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range